« Previous article
The Ongoing Pandemic...

7th September 2021  Content supplied by: Fapon Biotech Inc.

Highly-Specific Neutralizing Antibodies for COVID-19 Vaccine Potency and Immunity Studies


COVID-19 vaccines are a crucial tool to control the global epidemic and restore the economy. After vaccination, neutralizing antibodies (NAbs) will develop as an immune response to fight off the invading SARS-CoV-2 pathogen.

Hence to evaluate the effectiveness of a vaccine, it is essential to identify the presence and quantitative level of NAbs, ensuring the titer level needed is reached to fight against future virus encounters.

The current gold standard method uses the live virus neutralization model for NAb detection in vaccine clinical trials, which requires BSL3 laboratory cultivation and can not be applied as a large-scale conventional testing method.

Fapon Biotech COVID-19 NAb Test Solution provides alternative testing methods to gold standard live virus-based PRNT with high correlation in performances, solving the problems of requiring high laboratory safety level, long detection time, and quantification.

COVID-19 NAbs are an essential tool in vaccine evaluation as they can be used to measure the titer level of the immune response. They are also precise and pose a very low contamination risk.  

After several verifications, the Fapon NAb test reagents show impressive qualities in affinity, sensitivity, specificity, and correlation to sVNT (Surrogate Virus Neutralization Test), which can be applied in antibody-drug studies, vaccine potency assays, and more.

Key Points:

  • Innovative patented methodology for both neutralizing antibody and total antibody detection
  • Validated on ELISA, CLIA, Rapid Test, and Turbilatex platforms 
  • Excellent sensitivity & specificity
  • High correlation to gold standard PRNT & FDA EUA neutralizing antibody test kit

Please visit Fapon Biotech or use the 'Request Information' button provided below for more details. 


    

Tags:

Date Published: 7th September 2021

Source article link: View


View full company details